A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study)

समान संसाधन

• Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
  द्वारा: Kotaka, Masahito, और अन्य
  प्रकाशित: (2016)
• XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI
  द्वारा: SUZUKI, KOICHI, और अन्य
  प्रकाशित: (2014)
• Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
  द्वारा: Komatsu, Yoshito, और अन्य
  प्रकाशित: (2015)
• Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
  द्वारा: Suenaga, Mitsukuni, और अन्य
  प्रकाशित: (2015)
• A Successfully Resected Case of Recurrent Lung and Liver Metastases of Rectal Cancer Treated with XELIRI + Bevacizumab Therapy
  द्वारा: Aisu, Naoya, और अन्य
  प्रकाशित: (2013)